Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) EBITDA Margin: 2018-2025

Historic EBITDA Margin for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to -78.41%.

  • Arcturus Therapeutics Holdings' EBITDA Margin fell 6184.00% to -78.41% in Q3 2025 from the same period last year, while for Sep 2025 it was -68.35%, marking a year-over-year decrease of 2929.00%. This contributed to the annual value of -53.14% for FY2024, which is 3532.00% down from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' EBITDA Margin is -78.41%, which was down 141.73% from -32.44% recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' EBITDA Margin ranged from a high of 73.21% in Q4 2022 and a low of -2,727.69% during Q2 2021.
  • Moreover, its 3-year median value for EBITDA Margin was -37.94% (2023), whereas its average is -83.86%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by 228,570bps in 2021, then soared by 264,810bps in 2022.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' EBITDA Margin stood at -667.29% in 2021, then spiked by 74,050bps to 73.21% in 2022, then slumped by 11,115bps to -37.94% in 2023, then plummeted by 9,386bps to -131.80% in 2024, then tumbled by 6,184bps to -78.41% in 2025.
  • Its EBITDA Margin stands at -78.41% for Q3 2025, versus -32.44% for Q2 2025 and -47.91% for Q1 2025.